ѪС°å¼õÉÙÐÔ×Ïñ° ѪС°å¼õÉÙÐÔ×Ïñ°ÖÎÁÆ ±±¾©ÑªÒº²¡Ò½Ôº
»ñµÃÐÔѪ˨ÐÔѪС°å¼õÉÙÐÔ×Ïñ°(TTP)»¼ÕßÓÉÓÚѪ¹ÜÐÔѪÓѲ¡Òò×ÓÁѽ⵰°×øADAMTS 13ȱ·¦µ¼ÖÂѪ¹ÜÐÔѪÓѲ¡Òò×Ó¶à¾ÛÎѪС°åºÍ΢Ѫ˨ÎÞÏÞÕ³¸½£¬Òý·¢ÑªÐ¡°å¼õÉÙ¡¢ÈÜѪÐÔƶѪºÍ×é֯ȱѪ¡£Caplacizumab£¬Ò»ÖÖ¿¹ÑªÓѲ¡Òò×ÓµÄÈËÔ´»¯ÃâÒßÇòµ°°×£¬¿ÉÒÖÖƳ¬´óѪ¹Ü¼ÙÐÔѪÓѲ¡Òò×Ó¶à¾ÛÌåºÍѪС°å¼äµÄÏ໥×÷Óá£
Ñо¿·½·¨
ÔÚÕâÏî˫ä¶ÔÕÕÊÔÑéÖУ¬Ëæ»ú·ÖÅä145Ãû»¼ÓÐTTPµÄ»¼Õߣ¬ÔÚѪ½¬Öû»ºó30ÌìËæ»ú½ÓÊÜCaplacizumab(ÿÈÕ10mg)»ò°²Î¿¼Á¡£Ñо¿µÄÖ÷ÒªÖÕµãΪѪС°å¼ÆÊýÕý³£»¯(5ÌìÄÚֹͣÿÈÕѪ½¬½»»»)¡£´ÎÒªÖÕµã°üÀ¨TTPÏà¹ØËÀÍö¡¢TTP¸´·¢»òÊÔÑéÆÚ¼äѪ˨˨Èûʼþ¡£
Ñо¿½á¹û
?caplacizumabѪС°å¼ÆÊýÕý³£»¯µÄÖÐλʱ¼ä¶ÌÓÚ°²Î¿¼Á×飺(2.69Ìì[95%¿ÉÐÅÇø¼ä{CI}£¬1.89ÖÁ2.83]¶Ô2.88Ìì[95%CI£¬2.68ÖÁ3.56]£¬P = 0.01)
?½ÓÊÜcaplacizumabÖÎÁƵĻ¼ÕßѪС°å¼ÆÊýÕý³£»¯µÄ¿ÉÄÜÐÔÊÇ·þÓð²Î¿¼ÁµÄ»¼ÕßµÄ1.55±¶¡£
?ʹÓÃcaplacizumabµÄ¸´ºÏÖÕµãʼþ»¼Õ߱Ȱ²Î¿¼Á×éµÍ74%(12%¶Ô49%£¬P <0.001)¡£
?ÔÚÊÔÑéÆÚ¼äÈκÎʱ¼ä¸´·¢TTPµÄ»¼Õß±ÈÀýʹÓÃcaplacizumab±È°²Î¿¼ÁµÍ67%(12%¶Ô38%£¬P<0.001)¡£
?ÔÚcaplacizumab×éºÍ°²Î¿¼Á×éÖеÄ3Ãû»¼ÕßÖоùδ·¢ÉúÄÑÖÎÐÔ¼²²¡¡£
?½ÓÊÜcaplacizumabÖÎÁƵĻ¼Õ߱ȽÓÊÜ°²Î¿¼ÁµÄ»¼ÕßÐèÒª¸üÉÙµÄѪ½¬Öû»ºÍסԺʱ¼ä¸ü¶Ì¡£
?×î³£¼ûµÄ²»Á¼Ê¼þÊÇճĤƤ·ô³öѪ£¬¾Ý±¨µÀ£¬caplacizumab×éÓÐ65%µÄ»¼ÕߺͰ²Î¿¼Á×éÓÐ48%µÄ»¼Õß³öÏÖճĤƤ·ô³öѪ¡£
?ÔÚÊÔÑéÖÎÁÆÆڼ䣬°²Î¿¼Á×éÖÐÓÐ3Ãû»¼ÕßËÀÍö¡£ÔÚÖÎÁÆÆÚ½áÊøºó£¬caplacizumab×éÖеÄÒ»Ãû»¼ÕßËÀÓÚÄÔȱѪ¡£
Ñо¿½áÂÛ
ÔÚTTP»¼ÕßÖУ¬caplacizumabÖÎÁÆÓëѪС°å¼ÆÊýµÄ¸ü¿ìÕý³£»¯ÓйØ; ÔÚÖÎÁÆÆڼ䣬TTPÏà¹ØËÀÍö£¬TTP¸´·¢»òѪ˨˨ÈûʼþµÄ¸´ºÏ·¢ÉúÂʽϵÍ; ÊÔÑéÆÚ¼äTTPµÄ¸´·¢ÂʵÍÓÚ°²Î¿¼Á¡£